Breast Cancer: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Paula Anastasia,(1) RN, MN, AOCN®, and Wendy H. Vogel,(2) MSN, FNP, AOCNP®
(1) UCLA Health Medical Center; (2) Harborside
J Adv Pract Oncol 2020;11(6):591-600 |
© 2020 Harborside™
Paula Anastasia, RN, MN, AOCN®, of UCLA Health Medical Center, and Wendy H. Vogel, MSN, FNP, AOCNP®, of Harborside, discuss results from studies evaluating therapies in women with de novo metastatic breast cancer and HER2-positive breast cancer, along with targeted therapies for PIK3CA and ESR1 mutations. Reporting provided by The ASCO Post.
For access to the full length article, please sign in